Semaglutide for treating obesity-related heart failure

Semaglutide is in clinical development for the treatment of obesity-related heart failure with preserved ejection fraction (HFpEF). Obesity is a chronic disease and global public health challenge, and the prevalence of obesity is rising in the UK. Obesity increases the risk of developing a range of health conditions including a predisposition to risk factors associated with HF, such as cardiovascular disease, myocardial infraction and coronary artery disease. Currently, there are very limited effective and durable interventions available to reduce body weight and specifically target the increased cardiovascular risk associated with obesity.